Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison

Lancet

Volumn 369, Issue 9560, 2007, Pages 465-473

  Laine, Loren ^a   Curtis, Sean P ^b   Cryer, Byron ^c   Kaur, Amarjot ^b   Cannon, Christopher P ^d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ESOMEPRAZOLE; ETORICOXIB; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; METHOTREXATE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; SUCRALFATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG USE; DUODENAL ULCER BLEEDING; DUODENUM ULCER; FEMALE; GASTRIC ULCER BLEEDING; GASTROINTESTINAL OBSTRUCTION; HUMAN; JEJUNUM ULCER; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; OUTCOMES RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; STOMACH ULCER; UPPER GASTROINTESTINAL BLEEDING; UPPER GASTROINTESTINAL TRACT;

EID: 33846822336     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(07)60234-7     Document Type: Article

References (40)

1. Laine L. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs-nice or necessary?. Rev Gastroenterol Disord 4 suppl 4 (2004) S33-S41
2. Laine L., Margolis J., and Brown K. Use of GI protective agents and COX-2 selective inhibitors in 14 394 624 U.S. patients taking NSAIDs. Gastroenterology 126 suppl 2 (2004) A36-A37
3. Chan F., Chung S., Suen B., et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 344 (2001) 967-973
4. Lai K., Lam S., Chu K., et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 346 (2002) 2033-2038
5. FDA Arthritis Advisory Committee. Briefing information NDA 20-998/S009 Celebrex (celecoxib). http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1.htm (accessed Jan 18, 2007)
6. Bombardier C., Laine L., Reicin A., et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
7. Schnitzer T., Burmester G., Mysler E., et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364 (2004) 665-674
8. Singh G., Fort J., Goldstein J., et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Am J Med 119 (2006) 255-266
9. Laine L., Maller E., Yu C., Quan H., and Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 127 (2004) 395-402
10. Goldstein J., Lowry S., Lanza F., Schwartz H., and Dodge W. The impact of low-dose aspirin on endoscopic gastric and duodenal ulcer rates in users of a non-selective non-steroidal anti-inflammatory drug or a cyclo-oxygenase-2-selective inhibitor. Aliment Pharmacol Ther 23 (2006) 1489-1498
11. Goldstein J., Aisenberg J., Berger M., and Dodge W. Effects of concomitant aspirin (81 mg qd) on incidence of gastric and/or duodenal ulcers in healthy subjects taking celecoxib or naproxen: a randomized, placebo-controlled trial. Gastroenterology 130 suppl 2 (2006) A81
12. Rahme E., Bardou M., Dasgupta K., Tobouti Y., and Barkun A. Gastrointestinal effects of rofecoxib and celecoxib versus NSAIDs among patients on low dose aspirin. Gastroenterology 126 suppl 2 (2004) A1-A2
13. Larkai E., Smith J., Lidsky M., Sessoms S., and Graham D. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 11 (1989) 158-162
14. Scheiman J. Unmet needs in non-steroidal anti-inflammatory drug-induced upper gastrointestinal diseases. Drugs 66 suppl 1 (2006) 15-21
15. Labenz J., Blum A., Bolten W., et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomized, double blind, placebo controlled trial. Gut 51 (2002) 329-335
16. Yeomans N., Tulassay Z., Juhasz L., et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. N Engl J Med 338 (1998) 719-726
17. Hawkey C., Talley N., Yeomans N., et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 100 (2005) 1028-1036
18. Watson D., Harper S., Zhao P., Quan H., Bolognese J., and Simon T. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Intern Med 160 (2000) 2998-3003
19. Bensen W., Zhao S., Burke T., et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 27 (2000) 1876-1883
20. Eisen G., Goldstein J., Hanna D., and Rublee D. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Aliment Pharmacol Ther 21 (2005) 591-598
21. Goldstein J., Eisen G., Burke T., Pena B., Lefkowith J., and Geis G. Dyspepsia tolerability from the patients' perspective: a comparison of celecoxib with diclofenac. Aliment Pharmacol Ther 16 (2002) 809-827
22. Rabeneck L., Goldstein J., Vu A., Mayne T., and Rublee D. Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis. Am J Gastroenterol 100 (2005) 1043-1050
23. Cannon C., Curtis S., FitzGerald G., et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368 (2006) 1771-1781
24. Cannon C., Curtis S., Bolognese J., and Laine L. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib vs. diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 152 (2006) 237-245
25. Arnett F., Edworthy S., Bloch D., et al. The American rheumatism association 1987 revised criteria for the classification of rheumatiod arthritis. Arthritis Rheum 31 (1988) 315-324
26. Silverstein F., Graham D., Senior J., et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123 (1995) 241-249
27. Silverstein F., Faich G., Goldstein J., et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 284 (2000) 1247-1255
28. Laine L., Bombardier C., Hawkey C., et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 123 (2002) 1006-1012
29. Patrono C., Patrignani P., and Garcia Rodriguez L. Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 108 (2001) 7-13
30. Reilly I., and FitzGerald G. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood 69 (1987) 180-186
31. Grosser T., Fries S., and FitzGerald G. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest 116 (2006) 4-15
32. Catella-Lawson F., Reilly M., Kapoor S., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
33. Emery P., Zeidler H., Kvien K., et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 354 (1999) 2106-2111
34. Sikes D., Agrawal N., Zhao W., Kent J., Recker D., and Verburg K. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 14 (2002) 1101-1111
35. Pavelka K., Recker D., and Verburg K. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers: results of a 26-week trial. Rheumatology (Oxford) 42 (2003) 1207-1215
36. Van Hecken A., Schwartz J., Depré M., et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40 (2000) 1-12
37. Allum W., Griffin S., Watson A., Colin-Jones D., on behalf of the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, the British Society of Gastroenterology, and and the British Association of Surgical Oncology. Guidelines for the management of oesophageal and gastric cancer. Gut 50 suppl V (2002) v1-v23
38. Dubois R., Melmed G., Henning J., and Laine L. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 19 (2004) 197-208
39. Lanes S., Lanza L., Radensky P., et al. Resource utilization and cost of care for rheumatoid arthritis in a managed care setting. The importance of drug and surgery costs. Arthritis Rheum 40 (1997) 1475-1481
40. Laine L., Wogen J., and Yu H. Gastrointestinal healthcare resource utilization with chronic use of COX-2 specific inhibitors vs. traditional NSAIDs. Gastroenterology 125 (2003) 389-395